MAP2K5 and breast carcinoma: Our in silico analyses suggest that ER-negative and the basal-like and HER2-enriched intrinsic subtypes of breast cancer with low expression of MEK5-ERK5 do benefit from systemic treatments including chemotherapy, whereas patients with high expression of MEK5-ERK5 do not.